Commodore Capital LP Makes New $19.34 Million Investment in Zura Bio Limited $ZURA

Commodore Capital LP bought a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) in the 1st quarter, HoldingsChannel.com reports. The fund bought 3,250,000 shares of the company’s stock, valued at approximately $19,338,000. Zura Bio accounts for approximately 1.1% of Commodore Capital LP’s holdings, making the stock its 26th largest holding.

Several other large investors have also recently made changes to their positions in the company. Allworth Financial LP purchased a new stake in Zura Bio during the fourth quarter worth $30,000. Squarepoint Ops LLC grew its position in Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock valued at $177,000 after buying an additional 8,680 shares during the period. Bank of America Corp DE increased its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Zura Bio by 3.4% during the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after acquiring an additional 10,200 shares in the last quarter. Finally, Scientech Research LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth about $45,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, July 1st. William Blair initiated coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. Finally, Wall Street Zen lowered Zura Bio from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zura Bio has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Stock Performance

Shares of ZURA stock opened at $5.23 on Monday. Zura Bio Limited has a fifty-two week low of $1.35 and a fifty-two week high of $7.44. The stock’s fifty day moving average is $4.55 and its two-hundred day moving average is $5.37. The firm has a market capitalization of $496.22 million, a P/E ratio of -4.80 and a beta of -0.03.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, equities analysts forecast that Zura Bio Limited will post -0.76 earnings per share for the current year.

Zura Bio Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.